-
1
-
-
34748918351
-
Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: A meta-analysis
-
DOI 10.1016/S1470-2045(07)70281-4, PII S1470204507702814
-
Golfinopoulos V, Salanti G, Pavlidis N, et al: Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis. Lancet Oncol 8:898-911, 2007. (Pubitemid 47488054)
-
(2007)
Lancet Oncology
, vol.8
, Issue.10
, pp. 898-911
-
-
Golfinopoulos, V.1
Salanti, G.2
Pavlidis, N.3
Ioannidis, J.P.4
-
2
-
-
20544471876
-
Combined analysis of efficacy: The addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer
-
Kabbinavar FF, Hambleton J, Mass RD, et al: Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23:3706-3712, 2005.
-
(2005)
J Clin Oncol
, vol.23
, pp. 3706-3712
-
-
Kabbinavar, F.F.1
Hambleton, J.2
Mass, R.D.3
-
3
-
-
0030856731
-
Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders
-
Presta LG, Chen H, O'Connor SJ, et al: Humanization of an anti-vascular anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593-4599, 1997. (Pubitemid 27441066)
-
(1997)
Cancer Research
, vol.57
, Issue.20
, pp. 4593-4599
-
-
Presta, L.G.1
Chen, H.2
O'Connor, S.J.3
Chisholm, V.4
Meng, Y.G.5
Krummen, L.6
Winkler, M.7
Ferrara, N.8
-
4
-
-
34248173883
-
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
-
DOI 10.1200/JCO.2006.09.6305
-
Giantonio BJ, Catalano PJ, Meropol NJ, et al: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the eastern cooperative oncology group study E3200. J Clin Oncol 25:1539-1544, 2007. (Pubitemid 46733080)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.12
, pp. 1539-1544
-
-
Giantonio, B.J.1
Catalano, P.J.2
Meropol, N.J.3
O'Dwyer, P.J.4
Mitchell, E.P.5
Alberts, S.R.6
Schwartz, M.A.7
Benson III, A.B.8
-
5
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004.
-
(2004)
N Engl J Med
, vol.350
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
-
6
-
-
20544478429
-
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial
-
Kabbinavar FF, Schulz J, McCleod M, et al: Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23:3697-3705, 2005.
-
(2005)
J Clin Oncol
, vol.23
, pp. 3697-3705
-
-
Kabbinavar, F.F.1
Schulz, J.2
McCleod, M.3
-
7
-
-
49049105525
-
Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer results of the TREE study
-
Hochster HS, Hart LL, Ramanathan RK, et al: Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer results of the TREE study. J Clin Oncol 26:3523-3529, 2008.
-
(2008)
J Clin Oncol
, vol.26
, pp. 3523-3529
-
-
Hochster, H.S.1
Hart, L.L.2
Ramanathan, R.K.3
-
8
-
-
56749169353
-
Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: Results from a large observational cohort study (BRiTE)
-
Grothey A, Sugrue MM, Purdie DM, et al: Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol 26:5326-5334, 2008.
-
(2008)
J Clin Oncol
, vol.26
, pp. 5326-5334
-
-
Grothey, A.1
Sugrue, M.M.2
Purdie, D.M.3
-
9
-
-
36048960109
-
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C study
-
DOI 10.1200/JCO.2007.11.3357
-
Fuchs CS, Marshall J, Mitchell E, et al: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 25:4779-4786, 2007. (Pubitemid 350086481)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.30
, pp. 4779-4786
-
-
Fuchs, C.S.1
Marshall, J.2
Mitchell, E.3
Wierzbicki, R.4
Ganju, V.5
Jeffery, M.6
Schulz, J.7
Richards, D.8
Soufi-Mahjoubi, R.9
Wang, B.10
Barrueco, J.11
-
10
-
-
42949149159
-
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study
-
Saltz LB, Clarke S, Diaz-Rubio E, et al: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013-2017, 2008.
-
(2008)
J Clin Oncol
, vol.26
, pp. 2013-2017
-
-
Saltz, L.B.1
Clarke, S.2
Diaz-Rubio, E.3
-
11
-
-
84958699263
-
-
Safety and effectiveness of bevacizumab and chemotherapy in elderly patients with metastatic colorectal cancer: Results from the BRiTE observational cohort study. poster #4026
-
Kozloff MF, Sugrue MM, Purdie DM, et al: Safety and effectiveness of bevacizumab and chemotherapy in elderly patients with metastatic colorectal cancer: Results from the BRiTE observational cohort study. ASCO 2008 poster #4026.
-
ASCO 2008
-
-
Kozloff, M.F.1
Sugrue, M.M.2
Purdie, D.M.3
-
12
-
-
84958701134
-
-
Final efficacy results for bevacizumab plus standard first-line chemotherapies in patients with metastatic colorectal cancer: First BEAT. poster #4025
-
Berry RS, Van Cutsem E, Kretzschmar A, et al: Final efficacy results for bevacizumab plus standard first-line chemotherapies in patients with metastatic colorectal cancer: First BEAT. ASCO 2008 poster #4025.
-
ASCO 2008
-
-
Berry, R.S.1
Van Cutsem, E.2
Kretzschmar, A.3
-
13
-
-
0037531121
-
Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial
-
DOI 10.1200/JCO.2003.11.126
-
Rothenberg ML, Oza AM, Bigelow RH, et al: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 21:2059-2069, 2003. (Pubitemid 46606353)
-
(2003)
Journal of Clinical Oncology
, vol.21
, Issue.11
, pp. 2059-2069
-
-
Rothenberg, M.L.1
Oza, A.M.2
Bigelow, R.H.3
Berlin, J.D.4
Marshall, J.L.5
Ramanathan, R.K.6
Hart, L.L.7
Gupta, S.8
Garay, C.A.9
Burger, B.G.10
Le, B.N.11
Haller, D.G.12
-
14
-
-
1342290189
-
FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study
-
DOI 10.1200/JCO.2004.05.113
-
Tournigand C, Andre T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22:229-237, 2004. (Pubitemid 41095086)
-
(2004)
Journal of Clinical Oncology
, vol.22
, Issue.2
, pp. 229-237
-
-
Tournigand, C.1
Andre, T.2
Achille, E.3
Lledo, G.4
Flesh, M.5
Mery-Mignard, D.6
Quinaux, E.7
Couteau, C.8
Buyse, M.9
Ganem, G.10
Landi, B.11
Colin, P.12
Louvet, C.13
De Gramont, A.14
-
15
-
-
0033198035
-
CPT-11 (Irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer
-
DOI 10.1016/S0959-8049(99)00150-1, PII S0959804999001501
-
Andre T, Louvet C, Maindrault-Goebel F, et al: CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. Eur J Cancer 35:1343-1347, 1999. (Pubitemid 29397434)
-
(1999)
European Journal of Cancer
, vol.35
, Issue.9
, pp. 1343-1347
-
-
Andre, T.1
Louvet, C.2
Maindrault-Goebel, F.3
Couteau, C.4
Mabro, M.5
Lotz, J.P.6
Gilles-Amar, V.7
Krulik, M.8
Carola, E.9
Izrael, V.10
De Gramont, A.11
-
16
-
-
84958703655
-
-
Japanese source
-
-
-
|